PT - JOURNAL ARTICLE AU - Almanza-Reyes, Horacio AU - Moreno, Sandra AU - Plascencia-López, Ismael AU - Alvarado-Vera, Martha AU - Patrón-Romero, Leslie AU - Borrego, Belén AU - Reyes-Escamilla, Alberto AU - Valencia-Manzo, Daniel AU - Brun, Alejandro AU - Pestryakov, Alexey AU - Bogdanchikova, Nina TI - Evaluation of silver nanoparticles for the prevention of SARS-CoV-2 infection in health workers: <em>in vitro</em> and <em>in vivo</em> AID - 10.1101/2021.05.20.21256197 DP - 2021 Jan 01 TA - medRxiv PG - 2021.05.20.21256197 4099 - http://medrxiv.org/content/early/2021/05/22/2021.05.20.21256197.short 4100 - http://medrxiv.org/content/early/2021/05/22/2021.05.20.21256197.full AB - SARS-CoV-2 infection in hospital areas is of a particular concern, since the close interaction between health care personnel and patients diagnosed with COVID-19, which allows virus to be easily spread between them and subsequently to their families and communities. Preventing SARS-CoV-2 infection among healthcare personnel is essential to reduce the frequency of infections and outbreaks during the pandemic considering that they work in high-risk areas. In this research, silver nanoparticles (AgNPs) were tested in vitro and shown to have an inhibitory effect on SARS-CoV-2 infection in cultured cells. Subsequently, we assess the effects of mouthwash and nose rinse with ARGOVIT® silver nanoparticles (AgNPs), in the prevention of SARS-CoV-2 contagion in health workers consider as high-risk group of acquiring the infection in the General Tijuana Hospital, Mexico, a hospital for the exclusive recruitment of patients diagnosed with COVID-19. We present a prospective randomized study of 231 participants that was carried out for 9 weeks (during the declaration of a pandemic). The “experimental” group was instructed to do mouthwash and nose rinse with the AgNPs solution; the “control” group was instructed to do mouthwashes and nose rinse in a conventional way. The incidence of SARS-CoV-2 infection was significantly lower in the “experimental” group (two participants of 114, 1.8%) compared to the “control” group (thirty-three participants of 117, 28.2%), with a 84.8% efficiency. We conclude that the mouth and nasal rinse with AgNPs helps in the prevention of SARS-CoV-2 infection in health personnel who are exposed to patients diagnosed with COVID-19.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04894409Funding StatementA. Pestryakov Project VIU-RSCBMT-197/2020 Tomsk Polytechnic University https://tpu.ru/en The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The in vivo study was approved by the Research Ethics Committee of General Tijuana Hospital of the Institute of Public Health Services of the State of Baja California with favorable opinion number CONBIOETICA-02-CEI-001-20170 and was conducted in accordance with the Declaration of Helsinki. The favorable opinion was obtained written, we attach a copy in the support information.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available by the corresponsal author, please contact via e-mail almanzareyes@hotmail.com